top of page
This site was designed with the
.com
website builder. Create your website today.Start Now

  • Bonnet N, Bourgoin L, Biver E, Douni E, Ferrari S. (2020) “RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass”. Journal of Clinical Investigation; 129(8):3214-3223 2019. doi:10.1172/JCI138278

  • Papadaki M, Rinotas V, Violitzi F, Thireou T, Panayotou G, Samiotaki M,  Douni E (2019). New insights for RANKL as a proinflammatory modulator in modelled inflammatory arthritis. Frontiers in Immunology.10:97.  doi: 10.3389/fimmu.2019.00097

  • Melagraki G, Leonis G, Ntougkos E, Rinotas V, Papaneophytou C, Mavromoustakos T, Kontopidis G, Douni E, Kolias G, Afantitis A. (2018). Current Status and Future Prospects of Small–molecule Protein–protein Interaction (PPI) Inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL). Current Topics in Medicinal Chemistry; 18(8):661-673. doi: 10.2174/1568026618666180607084430.

  • Melagraki G, Ntougkos E, Papadopoulou D, Rinotas V, Leonis G, Douni E, Afantitis A, Kollias G. (2018). In Silico Discovery of Plant-Origin Natural Product Inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL). Frontiers in Pharmacology; 9:800. doi: 10.3389/fphar.2018.00800.

  • Melagraki G, Ntougkos E, Rinotas V, Papaneophytou C, Leonis G, Mavromoustakos T, Kontopidis G, Douni E, Afantitis A, Kollias G. (2017). Cheminformatics-aided discovery of small-molecule Protein-Protein Interaction (PPI) dual inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL). PLOS Computational Biology; 13(4): e1005372. doi: 10.1371/journal.pcbi.1005372.

  • Rinotas V, Niti A, Dacquin R, Bonnet N, Stolina M, Han C-Y, Douni E. (2014). Novel Genetic Models of Osteoporosis by Overexpression of Human RANKL in Transgenic Mice. Journal of Bone and Mineral Research, 29(5):1158–69. doi: 10.1002/jbmr.2112.

  • Papaneophytou CP, Rinotas V, Douni E, Kontopidis G. (2013). A statistical approach for optimization of RANKL overexpression in Escherichia coli: Purification and characterization of the protein. Protein Expression and Purification; 90(1):9-19. doi: 10.1016/j.pep.2013.04.005.

  • Papaneophytou CP, Mettou AK, Rinotas V, Douni E, Kondopidis GA. (2013). Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study. ACS Medicinal Chemistry  Letters; 4 (1):137–141. doi: 10.1021/ml300380h.

  • Douni E, Rinotas V, Makrinou E, Zwerina J, Penninger JM, Eliopoulos E, Schett G, Kollias. (2012). A RANKL G278R mutation causing osteopetrosis identifies a functional amino acid essential for trimer assembly in RANKL and TNF. Hum Mol Genet. 21(4):784-98. doi: 10.1093/hmg/ddr510

bottom of page